Neurobo Total Liab vs Net Working Capital Analysis

NRBO Stock

USD 2.40 0.05 2.04%

Neurobo Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Neurobo Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurobo Pharmaceuticals is a good investment. Please check the relationship between Neurobo Pharmaceuticals Total Liab and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.

Total Liab vs Net Working Capital

Total Liab vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurobo Pharmaceuticals Total Liab account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Neurobo Pharmaceuticals' Total Liab and Net Working Capital is -0.36. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Neurobo Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Neurobo Pharmaceuticals' Total Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Neurobo Pharmaceuticals are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Liab i.e., Neurobo Pharmaceuticals' Total Liab and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.36

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Working Capital

Most indicators from Neurobo Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurobo Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.At this time, Neurobo Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 22nd of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.23, while Issuance Of Capital Stock is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	48K	20K	3K	2.9K
Cost Of Revenue	72K	28K	7K	6.7K

Reconciled Depreciation Cost Of Revenue

Neurobo Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Non Current Liabilities Total	Non Current Liabilities Other	Net Tangible Assets
Total Assets		0.28	0.76	0.71	0.19	0.25	-0.95	-0.83	0.52	1.0	0.07	-0.23	1.0	0.87	0.33	0.83	0.39	0.78	0.28	1.0	-0.03	0.53	-0.83	0.05	0.18	0.43
Short Long Term Debt Total	0.28		-0.19	0.42	-0.45	-0.73	-0.01	0.0	0.65	0.27	0.31	0.2	0.27	0.21	-0.26	0.29	0.2	-0.11	0.56	0.27	0.58	0.28	-0.07	0.49	0.48	-0.61
Other Current Liab	0.76	-0.19		0.63	0.4	0.47	-0.82	-0.61	0.03	0.77	-0.16	-0.17	0.77	0.52	0.32	0.48	0.15	0.73	-0.04	0.77	-0.25	0.3	-0.58	-0.22	-0.08	0.58
Total Current Liabilities	0.71	0.42	0.63		-0.23	0.11	-0.54	-0.64	0.41	0.71	0.5	0.3	0.71	0.63	0.22	0.73	0.04	0.55	0.56	0.7	0.5	0.39	-0.38	0.33	0.17	0.08
Total Stockholder Equity	0.19	-0.45	0.4	-0.23		0.51	-0.41	-0.07	-0.11	0.19	-0.6	-0.14	0.19	-0.01	0.26	-0.1	0.33	0.49	-0.89	0.2	-0.91	-0.13	-0.54	-0.96	0.05	0.77
Current Deferred Revenue	0.25	-0.73	0.47	0.11	0.51		-0.43	-0.52	-0.24	0.26	0.11	0.08	0.26	0.36	0.53	0.35	0.04	0.64	-0.37	0.25	-0.41	0.0	-0.44	-0.49	-0.34	0.9
Net Debt	-0.95	-0.01	-0.82	-0.54	-0.41	-0.43		0.79	-0.33	-0.95	0.11	0.34	-0.95	-0.78	-0.44	-0.7	-0.44	-0.8	-0.03	-0.95	0.29	-0.41	0.87	0.17	-0.02	-0.62
Retained Earnings	-0.83	0.0	-0.61	-0.64	-0.07	-0.52	0.79		-0.46	-0.82	-0.23	0.23	-0.82	-0.93	-0.61	-0.9	-0.17	-0.82	-0.32	-0.82	-0.02	-0.37	0.78	-0.12	-0.14	-0.56
Accounts Payable	0.52	0.65	0.03	0.41	-0.11	-0.24	-0.33	-0.46		0.5	0.11	-0.09	0.5	0.61	-0.01	0.62	0.42	0.34	0.34	0.52	0.15	0.45	-0.59	0.2	0.71	-0.11
Cash	1.0	0.27	0.77	0.71	0.19	0.26	-0.95	-0.82	0.5		0.05	-0.25	1.0	0.86	0.33	0.82	0.38	0.77	0.27	1.0	-0.04	0.52	-0.83	0.04	0.18	0.43
Non Current Assets Total	0.07	0.31	-0.16	0.5	-0.6	0.11	0.11	-0.23	0.11	0.05		0.69	0.05	0.32	0.06	0.49	-0.12	0.07	0.62	0.05	0.8	0.16	0.15	0.52	-0.2	-0.18
Other Assets	-0.23	0.2	-0.17	0.3	-0.14	0.08	0.34	0.23	-0.09	-0.25	0.69		-0.25	-0.17	-0.16	0.04	-0.08	0.0	0.03	-0.25	0.47	-0.05	0.28	-0.05	-0.11	-0.12
Cash And Short Term Investments	1.0	0.27	0.77	0.71	0.19	0.26	-0.95	-0.82	0.5	1.0	0.05	-0.25		0.86	0.33	0.82	0.38	0.77	0.27	1.0	-0.04	0.52	-0.83	0.04	0.18	0.43
Common Stock Total Equity	0.87	0.21	0.52	0.63	-0.01	0.36	-0.78	-0.93	0.61	0.86	0.32	-0.17	0.86		0.41	0.97	0.37	0.78	0.41	0.86	0.11	0.53	-0.79	0.2	0.14	0.4
Common Stock Shares Outstanding	0.33	-0.26	0.32	0.22	0.26	0.53	-0.44	-0.61	-0.01	0.33	0.06	-0.16	0.33	0.41		0.35	-0.1	0.49	-0.07	0.33	-0.19	-0.5	-0.43	-0.17	-0.03	0.6
Capital Surpluse	0.83	0.29	0.48	0.73	-0.1	0.35	-0.7	-0.9	0.62	0.82	0.49	0.04	0.82	0.97	0.35		0.31	0.77	0.48	0.82	0.26	0.56	-0.73	0.24	0.16	0.34
Other Current Assets	0.39	0.2	0.15	0.04	0.33	0.04	-0.44	-0.17	0.42	0.38	-0.12	-0.08	0.38	0.37	-0.1	0.31		0.32	-0.15	0.39	-0.28	0.38	-0.53	-0.25	-0.14	0.12
Other Stockholder Equity	0.78	-0.11	0.73	0.55	0.49	0.64	-0.8	-0.82	0.34	0.77	0.07	0.0	0.77	0.78	0.49	0.77	0.32		-0.12	0.77	-0.27	0.35	-0.86	-0.36	0.12	0.75
Total Liab	0.28	0.56	-0.04	0.56	-0.89	-0.37	-0.03	-0.32	0.34	0.27	0.62	0.03	0.27	0.41	-0.07	0.48	-0.15	-0.12		0.26	0.87	0.35	0.14	0.96	0.04	-0.54
Total Current Assets	1.0	0.27	0.77	0.7	0.2	0.25	-0.95	-0.82	0.52	1.0	0.05	-0.25	1.0	0.86	0.33	0.82	0.39	0.77	0.26		-0.05	0.53	-0.84	0.04	0.18	0.43
Short Term Debt	-0.03	0.58	-0.25	0.5	-0.91	-0.41	0.29	-0.02	0.15	-0.04	0.8	0.47	-0.04	0.11	-0.19	0.26	-0.28	-0.27	0.87	-0.05		0.17	0.42	0.85	-0.02	-0.65
Common Stock	0.53	0.28	0.3	0.39	-0.13	0.0	-0.41	-0.37	0.45	0.52	0.16	-0.05	0.52	0.53	-0.5	0.56	0.38	0.35	0.35	0.53	0.17		-0.4	0.23	0.11	-0.01
Non Currrent Assets Other	-0.83	-0.07	-0.58	-0.38	-0.54	-0.44	0.87	0.78	-0.59	-0.83	0.15	0.28	-0.83	-0.79	-0.43	-0.73	-0.53	-0.86	0.14	-0.84	0.42	-0.4		0.35	-0.32	-0.67
Non Current Liabilities Total	0.05	0.49	-0.22	0.33	-0.96	-0.49	0.17	-0.12	0.2	0.04	0.52	-0.05	0.04	0.2	-0.17	0.24	-0.25	-0.36	0.96	0.04	0.85	0.23	0.35		-0.03	-0.68
Non Current Liabilities Other	0.18	0.48	-0.08	0.17	0.05	-0.34	-0.02	-0.14	0.71	0.18	-0.2	-0.11	0.18	0.14	-0.03	0.16	-0.14	0.12	0.04	0.18	-0.02	0.11	-0.32	-0.03		-0.1
Net Tangible Assets	0.43	-0.61	0.58	0.08	0.77	0.9	-0.62	-0.56	-0.11	0.43	-0.18	-0.12	0.43	0.4	0.6	0.34	0.12	0.75	-0.54	0.43	-0.65	-0.01	-0.67	-0.68	-0.1

Click cells to compare fundamentals

Neurobo Pharmaceuticals Account Relationship Matchups

Neurobo Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.5M	11.0M	16.8M	33.5M	22.8M	18.4M
Short Long Term Debt Total	116K	94K	71K	203K	182.7K	173.6K
Other Current Liab	1.4M	1.1M	1.3M	11.1M	5.0M	2.6M
Total Current Liabilities	2.1M	3.7M	2.2M	11.8M	6.0M	6.1M
Total Stockholder Equity	12.3M	7.2M	14.6M	21.8M	16.7M	17.5M
Net Debt	(13.8M)	(10.0M)	(16.3M)	(33.4M)	(22.2M)	(21.1M)
Retained Earnings	(36.9M)	(66.5M)	(81.8M)	(95.8M)	(108.3M)	(102.9M)
Accounts Payable	638K	2.6M	830K	708K	821K	1.1M
Cash	13.9M	10.1M	16.4M	33.4M	22.4M	17.8M
Non Current Assets Total	350K	285K	215K	2K	269K	220.2K
Cash And Short Term Investments	13.9M	10.1M	16.4M	33.4M	22.4M	17.8M
Common Stock Total Equity	18K	22K	16K	20K	23K	17.9K
Common Stock Shares Outstanding	21.8K	67.6K	96.4K	321.7K	5.1M	5.3M
Liabilities And Stockholders Equity	14.5M	11.0M	16.8M	33.5M	22.8M	18.4M
Capital Surpluse	64.4M	91.9M	49.1M	73.7M	84.8M	59.9M
Other Current Assets	42K	594K	197K	168K	77K	73.2K
Other Stockholder Equity	34.7M	73.7M	96.4M	117.5M	124.9M	69.3M
Total Liab	2.2M	3.8M	2.2M	11.8M	6.1M	5.8M
Total Current Assets	14.1M	10.7M	16.6M	33.5M	22.5M	18.1M
Short Term Debt	22K	48K	52K	134K	120.6K	114.6K
Common Stock	16K	20K	27K	25K	5K	4.8K
Non Currrent Assets Other	740K	350K	130K	21K	18.9K	18.0K
Non Current Liabilities Total	94K	70K	45K	708K	136K	129.2K
Net Tangible Assets	(13.3M)	12.3M	7.2M	14.6M	16.8M	17.6M
Net Invested Capital	12.3M	7.2M	14.6M	21.8M	16.7M	16.3M
Net Working Capital	12.0M	7.0M	14.4M	21.7M	16.6M	14.5M
Capital Stock	16K	20K	27K	25K	5K	4.8K

Pair Trading with Neurobo Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Neurobo Stock

0.67	ME	23Andme Holding	Pair Corr
0.84	VALN	Valneva SE ADR	Pair Corr
0.72	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against Neurobo Stock

0.76	KZR	Kezar Life Sciences	Pair Corr
0.6	MLYS	Mineralys Therapeutics,	Pair Corr
0.34	MDGL	Madrigal Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.

The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Neurobo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurobo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurobo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurobo Pharmaceuticals Stock:

How To Invest In Neurobo

Details

Is Neurobo Stock a good investment?

Details

What is Neurobo Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.29)

Return On Assets

(0.74)

Return On Equity

(1.61)

The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurobo Total Liab vs Net Working Capital Analysis

Total Liab vs Net Working Capital

Total Liab vs Net Working Capital Correlation Analysis

Correlation Coefficient

Total Liab

Net Working Capital

Neurobo Pharmaceuticals fundamental ratios Correlations

Neurobo Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurobo Pharmaceuticals fundamental ratios Accounts

Pair Trading with Neurobo Pharmaceuticals

Moving together with Neurobo Stock

Moving against Neurobo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Non Current Liabilities Total	- 0.96	Total Stockholder Equity
Total Current Assets	- 0.95	Net Debt
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Net Debt	- 0.95	Total Assets
Common Stock Total Equity	- 0.93	Retained Earnings